Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › HDM1702

HDM1702

GLP-1 · s.c. · Huadong Medicine

Data cut 12 November 2026 · page built 16 November 2026 · 1 trial arms · 1 trials with results · 1 registered trials · see on the pipeline board

Summary

Also known as
Zhongmei Huadong
Mechanism
GLP-1
Route
s.c.
Company
Huadong Medicine
Highest development stage
filed
Status (as of data cut)
Semaglutide follow-on: phase 3 equivalence to Wegovy; NDAs accepted in China (T2D Mar 2025; weight Apr 2026) verify
Next milestone
China approval

Sources for the status

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity3 positive phase 3Phase 3 equivalence versus Wegovy met (semaglutide follow-on)HDM1702 vs Wegovy (EASD 2026)
T2D0 no data
CV outcomes0 no data
CKD0 no data
HFpEF0 no data
MASH0 no data
Sleep apnoea0 no data
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
HDM1702 vs Wegovy (bioequivalence)HDM1702 2.4 mg vs semaglutide (Wegovy): −16.27 %obesity china44462—−15.2 %———————congress

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Registered trials (1)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
NCT07036172 · China
Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients
ObesityPhase 3recruiting2025-01 → 2026-04460recruitingNCT07036172

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: HDM1702. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/hdm1702/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.